ESMO 2018 Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer

ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer

12:13 EDT 21 Oct 2018 | ecancermedicalscience

Two-year maintenance therapy with olaparib, a PARP (poly ADP ribose polymerase) inhibitor, olaparib, led to a substantial, unprecedented improvement in progression-free survival (PFS) in newly diagnosed patients with advanced ovarian cancer and a BRCA1 or...

More From BioPortfolio on "ESMO 2018: Olaparib maintenance extends PFS by estimated 3 years in advanced ovarian cancer"